Sage Cognitive Performance Meta-analysis: What the Evidence Says

Quick Answer

Sage Cognitive Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• These structural and functional changes in muscle fibers associated with sarcopenia decrease the quality of life of this population due to increased probability of falls, fractures, low physical performance, and neurological disorders. [Garrido-Dzib Angel Gabriel (2026); evidence level 1]
• In this continuum, mild neurocognitive disorder, or mild cognitive impairment (MCI), corresponds to an intermediate clinical state in which there is objective evidence of moderate cognitive decline (e.g., in memory, learning, or language), without substantial impairment of functional or social autonomy. [Garrido-Dzib Angel Gabriel (2026); evidence level 1]
• From a public health perspective, these goals necessitate large-scale risk stratification in primary care and community settings, where resources are limited and decisions must be made at the population level. [Kim Seungmi (2026); evidence level 1]
• As a result, their measurement burden constrains scalability, limiting real-time screening and routine deployment in community-based practice. [Kim Seungmi (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For sage cognitive performance meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Garrido-Dzib Angel Gabriel (2026). A Systematic Review and Meta-analysis on the association between sarcopenia and cognitive impairment in middle-aged and older adults from Latin America. DOI: 10.1016/j.jnha.2026.100877. PMCID: PMC13213769. PMID: 42155950. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13213769/
• Kim Seungmi (2026). Machine Learning-Based Frailty Prediction and Classification in Community-Dwelling Older Adults: A Systematic Review of Validation, Explainability, and Implementation Readiness. DOI: 10.3390/healthcare14111543. PMCID: PMC13256724. PMID: 42278796. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256724/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.